Choroidal Neovascular Membrane in Pediatric Patients: Long-Term Outcomes of Anti-VEGF Therapy

English version

Autoři: Kamila Pavlíková ¹; Inka Krejčířová ¹; Rudolf Autrata ¹; Kateřina Šenková ¹; Veronika Matušková ²
Působiště autorů: Department of Pediatric Ophthalmology, University Hospital Brno and, Faculty of Medicine, Masaryk University, Brno, Czech Republic ¹; Department of Ophthalmology, University Hospital Brno and Faculty, of Medicine, Masaryk University, Brno, Czech Republic ²
Vyšlo v časopise: Čes. a slov. Oftal., 81, 2025, No. Ahead of Print, p. 1-8
Kategorie: Původní práce
doi: https://doi.org/10.31348/2025/33

Souhrn

Aim: To evaluate the epidemiological data, etiology and clinical characteristics, and to assess the efficacy and safety of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy in the treatment of choroidal neovascular membrane (CNV) in children and adolescents. The results are compared with data from previously published studies and case reports.

Material and Methods: Retrospective analysis of medical records of patients treated for CNV at the Department of Pediatric Ophthalmology, University Hospital Brno, between January 2015 and April 2025. The cohort consisted of 12 patients, including 7 males and 5 females. All the cases involved unilateral disease; the right eye was affected in 7 patients and the left eye in 5. The mean age at onset was 11.8 years (range: 3–17 years). All underwent a comprehensive ophthalmological examination including optical coherence tomography (OCT); in 7 cases the diagnosis was confirmed by fluorescein angiography. The evaluated parameters included epidemiological data, clinical and morphological characteristics of CNV before and after anti-VEGF therapy. The etiology of CNV in our cohort was as follows: post-inflammatory/post-infectious in 6 cases, idiopathic in 3 cases, and one case each of myopic, post-traumatic, and neoplastic origin. The most common localization was subfoveal. All CNV lesions were classified as classic (type 2).

Results: All patients achieved either anatomical or functional improvement. No ocular or systemic adverse effects related to intravitreal anti-VEGF therapy were observed during the study period.

Conclusion: Early diagnosis and intervention with anti-VEGF therapy show favorable outcomes, including stabilization and remission of the disease. In our cohort, no adverse events or complications associated with intravitreal anti-VEGF administration were recorded. Continued research is essential in order to gain a further understanding of the pathogenesis of pediatric CNV and to optimize treatment strategies in children.

Klíčová slova:

ranibizumab – anti-VEGF – choroidal neovascularization – pediatric CNV – choroidal neovascular membrane in children – secondary CNV

Zdroje

Rego-Lorca D, Català-Mora J, López-de-Eguileta A, Díaz-Cascajosa J. Choroidal neovascularization in children: etiology, clinical characteristics and treatment outcomes. Arch Soc Esp Oftalmol (Engl Ed). 2024 Dec;99(12):534-539.
Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ. Etiology of choroidal neovascularization in young patients. Ophthalmology. 1996 Aug;103(8):1241-1244.
Carneiro AM, Silva RM, Veludo MJ, et al. Ranibizumab treatment for choroidal neovascularization from causes other than age-related macular degeneration and pathological myopia. Ophthalmologica. 2011;225(2):81-88.
Goshorn EB, Hoover DL, Eller AW, Friberg TR, Jarrett WH, Sorr EM. Subretinal Neovascularization in Children and Adolescents. Journal of Pediatric Ophthalmology & Strabismus. 1995 May;32(3):178782.
Rishi P, Bharat RPK, Rishi E, et al. Choroidal neovascularization in 111 eyes of children and adolescents. Int Ophthalmol. 2022 Jan;42(1):157-166.
Zhang T, Wang Y, Yan W, et al. Choroidal Neovascularization in Pediatric Patients: Analysis of Etiologic Factors, Clinical Characteristics and Treatment Outcomes. Front Med (Lausanne). 2021;8 : 735805.
Moosajee M, Abbouda A, Foot B, Bunce C, Moore AT, Acheson J. Active surveillance of choroidal neovascularisation in children: incidence, aetiology and management findings from a national study in the UK. Br J Ophthalmol. 2018 Apr;102(4):438-443.
Niederer R, Bar A, Al-Ani H, et al. Management of inflammatory choroidal neovascular membranes. Expert Review of Ophthalmology. 2021 Jan 2;16(1):47-60.
Rishi P, Gupta A, Rishi E, Shah BJ. Choroidal neovascularization in 36 eyes of children and adolescents. Eye (Lond). 2013 Oct;27(10):1158-1168.
Secrétan M, Sickenberg M, Zografos L, Piguet B. Morphometric characteristics of traumatic choroidal ruptures associated with neovascularization. Retina. 1998;18(1):62-666.
Choroidal osteoma in old age (an unexpectedly difficult diagnosis). Acta Ophthalmol. 2018 Dec;96(S261):67-68.
Aksoy Y, Çakir Y, Sevinçli S, Sönmez M, Ayata A. Choroidal osteoma in a preterm infant. Ind J Ophthalmol. 2018 Apr;66(4):583-585.
Fine HF, Ferrara DC, Ho IV, Takahashi B, Yannuzzi LA. Bilateral choroidal osteomas with polypoidal choroidal vasculopathy. Retin Cases Brief Rep. 2008;2(1):15-17.
Huang YM, Zhang L, Liang J, Yuan RD. Bilateral choroidal osteoma with unilateral polypoidal choroidal vasculopathy treated with conbercept. Int J Ophthalmol. 2020;13(6):1009-1012.
Gómez PD, Català-Mora J, López-de-Eguileta A, Díaz-Cascajosa J. Bilateral choroidal osteoma: long-term follow-up of secondary choroidal neovascularization in a child using antiangiogenic therapy. Japoos. 2024;Vol 28: Issue 2103869. doi:10.1016/j.jaapos.2024.103869
Zhang L, Ran QB, Lei CY, Zhang MX. Clinical features and therapeutic management of choroidal osteoma: A systematic review. Survey of Ophthalmology. 2023 Nov 1;68(6):1084-1092.
Saitta A, Nicolai M, Neri P, Reibaldi M, Giovannini A, Mariotti C. Rescue therapy with intravitreal aflibercept for choroidal neovascularization secondary to choroidal osteoma non-responder to intravitreal bevacizumab and ranibizumab. Int Ophthalmol. 2015 Jun;35(3):441-444.
Rego-Lorca D, Català-Mora J, López-de-Eguileta A, Díaz-Cascajosa J. Choroidal neovascularization in children: etiology, clinical characteristics and treatment outcomes. Archivos de la Sociedad Española de Oftalmología (English Edition). 2024 Dec;99(12):534-539.
Padhi TR, Anderson BJ, Abbey AM, et al. Choroidal neovascular membrane in paediatric patients: clinical characteristics and outcomes. Br J Ophthalmol. 2018 Sep;102(9):1232-1237.
Barth T, Zeman F, Helbig H, Oberacher-Velten I. Etiology and treatment of choroidal neovascularization in pediatric patients. Eur J Ophthalmol. 2016 Oct;26(5):388-393.
Kozak I, Mansour A, Diaz RI, et al. Outcomes of treatment of pediatric choroidal neovascularization with intravitreal antiangiogenic agents: the results of the KKESH International Collaborative Retina Study Group. Retina. 2014 Oct;34(10):2044-2052.
Kim R, Kim YC. Intravitreal ranibizumab injection for idiopathic choroidal neovascularization in children. Semin Ophthalmol. 2014 May;29(3):178-181.
Ranjan R, Salian R, Verghese S, et al. Pediatric choroidal neovascularization: Etiology and treatment outcomes with anti-vascular endothelial growth factors. Eur J Ophthalmol. 2022 Jul;32(4):2355-2367.
Sivaprasad S, Moore AT. Choroidal neovascularisation in children. Br J Ophthalmol. 2008 Apr;92(4):451-454.
Finn AP, Fujino D, Lum F, Rao P. Etiology, Treatment Patterns, and Outcomes for Choroidal Neovascularization in the Pediatric Population: An Intelligent Research in Sight (IRIS®) Registry Study. Ophthalmology Retina. 2022 Feb 1;6(2):130-138.